• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    New Procedure Codes Might Change The Case For Investing In Inspire Medical Systems Stock (INSP)

    Simply Wall St·10/24/2026 16:33:23
    语音播报
    • Inspire Medical Systems recently secured new Category I CPT codes from the American Medical Association for single lead hypoglossal nerve stimulation procedures, effective from 2028. This coincides with Project Horizon, which redirects about US$30 million a year toward expanding patient access, education, and engagement.
    • The combination of clearer future coding for Inspire V and internal cost reallocation through Project Horizon directly targets reimbursement friction, administrative effort, and pathway bottlenecks that influence procedure volumes and operating efficiency.
    • We will now look at how Inspire Medical Systems' investment narrative could shift as reimbursement clarity around Inspire V improves.

    Scan how Inspire Medical Systems fits into a broader shift toward procedure driven healthcare by reviewing our hand picked 34 healthcare AI stocks moving on reimbursement and access catalysts.

    Inspire Medical Systems Investment Narrative Recap

    For Inspire Medical Systems, the core belief is that obstructive sleep apnea remains under treated and that a device based therapy can support a recurring procedure base over time. The short term swing factor is still how quickly reimbursement friction eases for Inspire V and how efficiently centers move from disrupted WISeR related workflows back to steadier implant activity.

    The biggest near term risk is that coding complexity, physician economics and lingering WISeR issues keep procedure volumes below what recent pricing and access changes can support. The new Category I CPT codes and Project Horizon funding help clarify the path, but legal scrutiny and potential revenue pressure from a slower Inspire V rollout remain key watchpoints.

    The coding decision from the American Medical Association is the clearest recent operational milestone tied to the current move in Inspire Medical Systems shares. Having Category I CPT codes defined for single lead hypoglossal nerve stimulation, including Inspire V, from 2028 gives hospitals, ambulatory surgery centers and physicians a more concrete framework for long term planning.

    That clarity intersects directly with Project Horizon, which frees up about US$30 million each year to support patient access, education and engagement. Together they aim to reduce prior authorization friction, cut administrative effort and support more predictable throughput, while still leaving open the risk that physician fee cuts or coding education gaps weigh on actual implant trends.

    Inspire Medical Systems is currently framed around analyst expectations that revenues reach US$983.3 million and earnings come in at US$76.9 million by 2029. These expectations are built on a 3.0% yearly revenue growth rate and an earnings decline of US$58.1 million from US$135.0 million today.

    Uncover why Inspire Medical Systems' fair value indicates a 4% potential downside to its current price, leaving little room for error.

    NYSE:INSP 1-Year Stock Price Chart
    NYSE:INSP 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate angle on Inspire Medical Systems is the concern that digital at-home sleep solutions and GLP-1 drugs could steadily siphon demand from implant-based therapy. The most pessimistic analysts were projecting just US$947.1 million of revenue and US$29.0 million of earnings by 2029, which is far below consensus. Those views were formed before the coding decision and Project Horizon updates, so it may be useful to compare several viewpoints and consider whether this news might eventually influence those assumptions.

    Explore 3 other Inspire Medical Systems fair value estimates, including one that suggests as much as 44% downside from the current price.

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Investment Ideas Beyond Inspire Medical Systems?

    Once you have a view on Inspire Medical Systems, it can help to compare it with other opportunities that fit different portfolio roles, whether you want potential mispricing, resilience, or income strength. The Simply Wall St Screener lets you quickly filter listed businesses by fundamentals, risk profile and balance sheet quality so you can build a shortlist that actually matches your goals.

    • If you are hunting for possible mispriced opportunities with quality fundamentals, start with a focused set of 27 high quality undervalued stocks that may warrant a closer look.
    • For investors who care more about balance sheet strength and durability through different conditions, filter for companies in the list of solid balance sheet and fundamentals (25 results) that might suit a more conservative allocation.
    • Income focused portfolios can begin with a targeted universe of 5 dividend fortresses that already clear a 5% yield hurdle and then apply your own quality filters on top.